Oncolytic Adenovirus Market Report 2026

The oncolytic adenovirus market size has grown strongly in recent years. It will grow from $132.49 billion in 2025 to $143.57 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to development of first-generation adenovirus-based therapies, increasing prevalence of melanoma and prostate cancer, rising investment in oncolytic virus research, early adoption by cancer research institutes, growing collaborations between biotech and academic institutions.

The oncolytic adenovirus market size is expected to see strong growth in the next few years. It will grow to $195.85 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising demand for engineered adenovirus therapies, increasing adoption in breast, ovarian, and lung cancers, growth in biotechnology company participation, rising funding for clinical trials and R&D, expansion of hospital and research institute capabilities in gene therapy. Major trends in the forecast period include rising adoption of ai and big data in oncolytic virus research, increasing application of genomics and precision medicine in virus engineering, growing use of digital platforms for clinical trial monitoring, rising automation in viral production and quality control, increasing iot-enabled monitoring of virus storage and distribution.

The rising incidence of cancer is expected to drive the growth of the oncolytic adenovirus market in the coming years. Cancer is a disease marked by uncontrolled cell growth that can spread to other parts of the body. Factors contributing to the increasing incidence of cancer include aging populations, lifestyle choices, environmental exposures, genetic predispositions, and improved detection methods. Oncolytic adenoviruses selectively target and kill cancer cells, offering a promising approach to address this growing disease burden. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported nearly 20 million new cancer cases and 9.7 million deaths worldwide, with projections for 2040 rising to 29.9 million cases and 15.3 million deaths. Additionally, in 2023, the Australian Bureau of Statistics reported that 1.8% of Australians had cancer, with men (2.1%) slightly more affected than women (1.6%), particularly those aged 75 and older. Therefore, the increasing prevalence of cancer is fueling growth in the oncolytic adenovirus market.

The growing adoption of personalized medicine is also expected to propel the oncolytic adenovirus market forward. Personalized medicine involves tailoring treatments to individual patients based on genetic, biomarker, phenotypic, or psychosocial characteristics to maximize efficacy and minimize toxicity. Advances in understanding tumor biology and the ability to design therapies targeting specific mutations or biomarkers have accelerated this approach, improving treatment outcomes and patient safety. Oncolytic adenoviruses align with personalized medicine by enabling highly targeted viral therapies that selectively infect and destroy cancer cells. For instance, in February 2024, the Personalized Medicine Coalition reported that 26 new personalized treatments were approved by the U.S. FDA in 2023, including 20 molecular entities and 6 gene- or cell-based therapies. Consequently, the expanding adoption of personalized medicine is supporting the growth of the oncolytic adenovirus market.

Leading companies in the oncolytic adenovirus market are developing combination therapies such as VCN-01, which pairs oncolytic virotherapy with chemotherapy to improve tumor targeting and enhance therapeutic outcomes. VCN-01 is engineered to selectively infect and destroy cancer cells while boosting the effectiveness of chemotherapy. For example, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its lead candidate, VCN-01, when used in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic adenocarcinoma. VCN-01 targets and replicates within tumor cells, breaking down the tumor stroma, a critical barrier to effective cancer treatment.

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

North America was the largest region in the oncolytic adenovirus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncolytic adenovirus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the oncolytic adenovirus market by increasing costs of viral vectors, lab equipment, and specialized reagents, affecting hospitals, cancer research institutes, and biotechnology companies primarily in north america, europe, and asia-pacific. While tariffs raise operational expenses, they also encourage local production, investment in domestic manufacturing, and diversification of supply chains, strengthening overall market resilience and reducing dependency on imports.

The oncolytic adenovirus market research report is one of a series of new reports that provides oncolytic adenovirus market statistics, including oncolytic adenovirus industry global market size, regional shares, competitors with a oncolytic adenovirus market share, detailed oncolytic adenovirus market segments, market trends and opportunities, and any further data you may need to thrive in the oncolytic adenovirus industry. This oncolytic adenovirus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oncolytic adenovirus is a genetically engineered virus created to selectively infect and kill cancer cells while leaving healthy tissue unharmed. It replicates within tumor cells, causing them to burst and release new viral particles that continue to target the cancer. In addition, it activates the immune system to strengthen the body’s anti-tumor response.

The main types of oncolytic adenoviruses include adenovirus type 5-based oncolytic viruses, adenovirus type 2-based oncolytic viruses, and other virus types. Adenovirus type 5-based oncolytic viruses are specifically modified to target and destroy cancer cells while sparing normal tissues. They are used to treat cancers such as melanoma, prostate cancer, breast cancer, ovarian cancer, lung cancer, and others, and are employed by end users including hospitals, cancer research institutes, biotechnology companies, and academic and research institutions.

The oncolytic adenovirus market consists of revenues earned by entities by providing services such as virus engineering and customization, clinical trial management, regulatory consulting, and contract research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncolytic adenovirus market also includes sales of therapies, customized viral vectors, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.